Duloxetine
- Generic Name
- Duloxetine
- Brand Names
- Cymbalta, Drizalma, Irenka, Yentreve, Duloxetine Zentiva, Duloxetine Mylan, Duloxetine Lilly
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19NOS
- CAS Number
- 116539-59-4
- Unique Ingredient Identifier
- O5TNM5N07U
- Background
Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor. It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval for a variety of indications including the tre...
- Indication
Indicated for:
1) Management of Major Depressive Disorder.
2) Management of Generalized Anxiety Disorder.
3) Management of diabetic peripheral neuropathy.
4) Management of fibromyalgia.
5) Management of chronic musculoskeletal pain.
6) Management of osteoarthritis of the knee in adults.
7) Management of chronic lower back pain in adults.
...
- Associated Conditions
- Chronic Lower Back Pain (CLBP), Chronic Musculoskeletal Pain, Diabetic Peripheral Neuropathic Pain (DPN), Fibromyalgia, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Osteoarthritis of the Knee, Stress Urinary Incontinence (SUI)
- Associated Therapies
- -
The Role of Central Serotonergic and Adrenergic Systems in the Effectiveness of DNIC (Diffuse Noxious Inhibitory Control
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2017-10-11
- Lead Sponsor
- Rambam Health Care Campus
- Target Recruit Count
- 64
- Registration Number
- NCT00660751
- Locations
- 🇮🇱
Rambam Health Care Campus, Haifa, Israel
Randomised Placebo-controlled Duloxetine-referenced Efficacy and Safety Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder
- Conditions
- Interventions
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2014-02-11
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 766
- Registration Number
- NCT00635219
Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy
- Conditions
- Interventions
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2018-09-11
- Lead Sponsor
- Wake Forest University
- Target Recruit Count
- 22
- Registration Number
- NCT00619983
- Locations
- 🇺🇸
Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
Duloxetine for the Treatment of Postpartum Depression
- Conditions
- Interventions
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2016-06-17
- Lead Sponsor
- Yale University
- Registration Number
- NCT00617045
- Locations
- 🇺🇸
Perinatal & Postpartum Research Program 142 Temple ST Suite 301, New Haven, Connecticut, United States
A Single-Blind Placebo Run-in Study of Duloxetine for Activity-Limiting Osteoarthritis Pain
- First Posted Date
- 2008-02-07
- Last Posted Date
- 2008-02-07
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 25
- Registration Number
- NCT00609557
Study of Duloxetine vs Placebo in Treatment of Binge Eating Disorder With Depression
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2017-08-21
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 40
- Registration Number
- NCT00607789
- Locations
- 🇺🇸
University of Cincinnati and Lindner Center of HOPE, Cincinnati, Ohio, United States
Safety and Efficacy Study of ADL5859 in Participants With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
- Conditions
- Interventions
- First Posted Date
- 2008-01-29
- Last Posted Date
- 2015-07-01
- Target Recruit Count
- 226
- Registration Number
- NCT00603265
- Locations
- 🇺🇸
Advanced Regional Center for Clinical Research (Ankle & Foot Care), Altoona, Pennsylvania, United States
🇺🇸Aquilo Research, Yukon, Oklahoma, United States
🇺🇸Panhandle Family Care Associates & Emerald Coast Research Grp, Inc., Marianna, Florida, United States
Dose-finding Study With Lu AA24530 in Major Depressive Disorder
- Conditions
- Interventions
- First Posted Date
- 2008-01-24
- Last Posted Date
- 2016-11-08
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 652
- Registration Number
- NCT00599911
- Locations
- 🇺🇦
UA001, Odessa, Ukraine
🇺🇦UA005, Kharkov, Ukraine
🇧🇪BE003, Diest, Belgium
Getting Biased Treatment Study: How Psychotherapy and Antidepressants Change Brain Activity in Chronic Depression
- Conditions
- Interventions
- First Posted Date
- 2008-01-17
- Last Posted Date
- 2009-08-03
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 30
- Registration Number
- NCT00596986
- Locations
- 🇩🇪
Charité Universitätsmedizin, Berlin, Germany
Duloxetine - Warfarin Pharmacodynamic Study
- Conditions
- Interventions
- First Posted Date
- 2007-09-21
- Last Posted Date
- 2008-10-02
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 60
- Registration Number
- NCT00533026
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician, Leeds, West Yorkshire, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.